2026年3月3日, 学者Rock(SRRK)股票上升, 尽管季度损失和内幕销售增加, Scholar Rock (SRRK) stock rose on March 3, 2026, despite a larger quarterly loss and insider sales, buoyed by strong analyst sentiment and its lead drug candidate in development.

学者Rock(SRRK)股票在2026年3月3日暴涨,每股季度亏损0.88美元,略低于估计数,而一年前亏损0.64美元,随后以45.25美元开始。 Scholar Rock (SRRK) shares surged on March 3, 2026, opening at $45.25 after a quarterly loss of $0.88 per share, slightly below estimates, compared to a loss of $0.64 a year earlier. 尽管过去90天内部销售总额达1 540万美元,而且一家公司的销售评级为 " 销售 " ,但股票持有协商一致的 " Buy " 评级,平均目标价为51.14美元。 Despite insider sales totaling $15.4 million in the past 90 days and a Sell rating from one firm, the stock holds a consensus “Buy” rating with a $51.14 average target price. 该公司是一个临床生物技术阶段开发蛋白质治疗技术的公司,拥有47.8亿美元的市场上限,机构所有权很高,占91.08%。 The company, a clinical-stage biotech developing protein therapeutics, has a $4.78 billion market cap and high institutional ownership at 91.08%. 其主要候选人SRK-015正在研发脊椎肌肉萎缩。 Its lead candidate, SRK-015, is in development for spinal muscular atrophy.